News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
277,217 Results
Type
Article (14273)
Company Profile (46)
Press Release (262893)
Multimedia
Podcasts (26)
Webinars (10)
Section
Business (81830)
Career Advice (672)
Deals (11536)
Drug Delivery (63)
Drug Development (43433)
Employer Resources (69)
FDA (5533)
Job Trends (6898)
News (140490)
Policy (11814)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (1354)
Academic (1)
Accelerated approval (32)
Adcomms (7)
Allergies (89)
Alliances (21436)
ALS (125)
Alzheimer's disease (914)
Antibody-drug conjugate (ADC) (199)
Approvals (5687)
Artificial intelligence (260)
Autoimmune disease (153)
Automation (14)
Bankruptcy (111)
Best Places to Work (5916)
BIOSECURE Act (6)
Biosimilars (57)
Biotechnology (37)
Bladder cancer (95)
Brain cancer (43)
Breast cancer (348)
Cancer (2989)
Cardiovascular disease (222)
Career advice (548)
Career pathing (18)
CAR-T (188)
CDC (19)
Cell therapy (478)
Cervical cancer (13)
Clinical research (38424)
Collaboration (1064)
Company closure (3)
Compensation (434)
Complete response letters (28)
COVID-19 (1108)
CRISPR (62)
C-suite (569)
Cystic fibrosis (103)
Data (4261)
Decentralized trials (1)
Denatured (2)
Depression (103)
Dermatology (40)
Diabetes (282)
Diagnostics (1954)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (23)
Drug discovery (166)
Drug pricing (124)
Drug shortages (5)
Duchenne muscular dystrophy (176)
Earnings (34763)
Editorial (26)
Employer branding (9)
Employer resources (61)
Events (44781)
Executive appointments (527)
FDA (7389)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (19)
Funding (993)
Gene editing (152)
Generative AI (23)
Gene therapy (461)
GLP-1 (518)
Government (2178)
Grass and pollen (1)
Guidances (244)
Healthcare (9213)
HIV (48)
Huntington's disease (30)
IgA nephropathy (68)
Immunology and inflammation (163)
Immuno-oncology (52)
Indications (99)
Infectious disease (1250)
Inflammatory bowel disease (135)
Inflation Reduction Act (10)
Influenza (57)
Intellectual property (166)
Interviews (71)
IPO (6529)
IRA (44)
Job creations (1197)
Job search strategy (486)
JPM (33)
Kidney cancer (13)
Labor market (29)
Layoffs (320)
Leadership (12)
Legal (1616)
Liver cancer (51)
Longevity (15)
Lung cancer (379)
Lymphoma (244)
Machine learning (33)
Management (27)
Manufacturing (380)
MASH (120)
Medical device (3328)
Medtech (3346)
Mergers & acquisitions (5436)
Metabolic disorders (769)
mRNA (102)
Multiple sclerosis (123)
NASH (15)
Neurodegenerative disease (249)
Neuropsychiatric disorders (61)
Neuroscience (1798)
Neurotech (1)
NextGen: Class of 2026 (3094)
Non-profit (3240)
Now hiring (22)
Obesity (329)
Opinion (117)
Ovarian cancer (123)
Pain (109)
Pancreatic cancer (149)
Parkinson's disease (218)
Partnered (18)
Patents (274)
Patient recruitment (349)
Peanut (32)
People (25465)
Pharmaceutical (10)
Pharmacy benefit managers (12)
Phase 1 (12367)
Phase 2 (17316)
Phase 3 (13008)
Pipeline (4577)
Policy (143)
Postmarket research (738)
Preclinical (4941)
Press Release (16)
Prostate cancer (159)
Psychedelics (29)
Radiopharmaceuticals (184)
Rare diseases (669)
Real estate (1683)
Recruiting (27)
Regulatory (10474)
Reports (14)
Research institute (1167)
Resumes & cover letters (146)
Rett syndrome (28)
RNA editing (11)
RSV (31)
Schizophrenia (100)
Series A (170)
Series B (121)
Service/supplier (1)
Sickle cell disease (80)
Special edition (5)
Spinal muscular atrophy (117)
Sponsored (19)
Startups (1575)
Stomach cancer (7)
Supply chain (23)
Tariffs (25)
The Weekly (23)
Vaccines (435)
Venture capital (52)
Weight loss (190)
Women's health (48)
Worklife (5)
Date
Today (78)
Last 7 days (401)
Last 30 days (1618)
Last 365 days (15781)
2026 (4217)
2025 (15336)
2024 (16939)
2023 (19685)
2022 (22509)
2021 (25138)
2020 (23590)
2019 (21147)
2018 (16071)
2017 (13497)
2016 (12045)
2015 (13926)
2014 (9593)
2013 (7206)
2012 (7669)
2011 (8346)
2010 (7357)
Location
Africa (256)
Alabama (46)
Alaska (3)
Arizona (97)
Arkansas (6)
Asia (14124)
Australia (3069)
California (6290)
Canada (1501)
China (461)
Colorado (213)
Connecticut (325)
Delaware (187)
Europe (39473)
Florida (934)
Georgia (180)
Hawaii (2)
Idaho (16)
Illinois (438)
India (30)
Indiana (245)
Iowa (9)
Japan (302)
Kansas (43)
Kentucky (16)
Louisiana (15)
Maine (7)
Maryland (657)
Massachusetts (5050)
Michigan (84)
Minnesota (195)
Mississippi (3)
Missouri (64)
Montana (11)
Nebraska (13)
Nevada (43)
New Hampshire (26)
New Jersey (1537)
New Mexico (7)
New York (1952)
North Carolina (756)
North Dakota (4)
Northern California (3182)
Ohio (188)
Oklahoma (8)
Oregon (13)
Pennsylvania (1260)
Puerto Rico (7)
Rhode Island (17)
South America (361)
South Carolina (27)
South Dakota (1)
Southern California (2432)
Tennessee (70)
Texas (963)
United States (22065)
Utah (131)
Virginia (132)
Washington D.C. (35)
Washington State (570)
Wisconsin (44)
277,217 Results for "encorps teachers program".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.
March 19, 2026
·
2 min read
·
Heather McKenzie
FDA
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma leaders try to decode the criteria for investigational or approved drugs to receive a voucher.
March 23, 2026
·
7 min read
·
Heather McKenzie
Manufacturing
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home
The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the design of their facilities.
February 2, 2026
·
2 min read
·
Tristan Manalac
Legal
AbbVie Sues HHS, CMS for Including Botox in Drug Price Negotiation Program
AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.
February 12, 2026
·
1 min read
·
Tristan Manalac
Press Releases
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program
• Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials • Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue Systems
March 23, 2026
·
7 min read
FDA
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says
Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior reviewers, according to Auchincloss.
February 4, 2026
·
2 min read
·
Tristan Manalac
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
·
2 min read
·
Dan Samorodnitsky
Rare diseases
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate’s ICE Fight
The Senate failed to pass a massive spending bill on Thursday—which includes the rare pediatric PRV program but also funding for the Immigration and Customs Enforcement’s large-scale crackdown in Minnesota and other states.
January 30, 2026
·
3 min read
·
Annalee Armstrong
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.
December 9, 2025
·
2 min read
·
Heather McKenzie
1 of 27,722
Next
